Abivax SA reported a net loss of €165.9 million for the first half of 2026, widening from €100.8 million in the same period last year. The clinical-stage biotechnology company’s operating loss expanded to €140.3 million, driven by increased research and development expenses ahead of potential commercialization.

The company’s statutory auditors reviewed the half-year financial statements, which were approved by the Board of Directors on September 18, 2026. Abivax filed the reports with French and U.S. securities regulatory authorities on September 21, 2026. Following the release, Abivax shares fell 0.1% to $103.41 in pre-market trading.

Analyst Rating Updates

Wedbush analyst David Nierengarten maintains a Neutral rating on Abivax (NASDAQ: ABVX) but lowered the price target to $118 from $140. This adjustment follows the release of the company's H1FY26 financial results and reflects updated valuation assumptions regarding the pipeline progression.

Truist Securities analyst Gregory Renza maintained the stock with a Buy rating but lowered the price target to $151 from $155. Both adjustments reflect the impact of the wider losses and current cash burn rates on near-term valuation models.

Financial Performance

Total operating income remained minimal at €2.5 million, up slightly from €2.1 million in H1FY25. However, total operating expenses rose significantly to €142.8 million (derived from components) from €96.7 million in the prior year period.

Research and development costs accounted for 75.5% of operating expenses in H1FY26, down from 81.3% in H1FY25, despite the absolute increase in spend. The rise was driven by progression in ulcerative colitis and Crohn’s disease clinical programs, as well as increased chemistry, manufacturing, and controls costs.

General and administrative expenses increased by €14.1 million to €30.4 million, primarily due to an €8.6 million rise in personnel costs linked to share-based compensation. Sales and marketing expenses tripled to €4.6 million as the company prepared for potential future sales efforts in the U.S.

Earnings Per Share and Revenue Estimates

On a per-share basis, Abivax reported losses of $(2.43), missing the analyst consensus estimate of $(1.08) by 125%. This represents a 65.31% decrease over losses of $(1.47) per share from the same period last year.

The company reported quarterly sales of $2.959 million, beating the analyst consensus estimate of $1.860 million by 59.09%. This is a 61.71% decrease over sales of $7.727 million in the same period last year.

Balance Sheet and Cash Position

As of June 30, 2026, Abivax held cash, cash equivalents, and short-term investments totaling €402.4 million. This figure includes €14.4 million in short-term investments. Total assets decreased to €462.2 million from €584.3 million at the end of 2025.

In early July 2026, the company completed an underwritten public offering of American Depositary Shares, generating net proceeds of approximately €767.1 million (€807.4 million gross). Combined with its existing cash position, Abivax projects a cash runway into Q4 2029 based on current operating assumptions.

The company also completed the repurchase and cancellation of all outstanding royalty certificates in May 2026 for a total consideration of $90 million (approximately €76.5 million). This transaction resulted in a €43.2 million expense in Q2 2026 and the derecognition of a €5.8 million deferred tax liability.

What the Numbers Show

The royalty certificate buy-back materially altered the balance sheet structure. While total liabilities fell to €95.9 million from €129.1 million year-end 2025, shareholders’ equity also declined to €366.3 million from €455.2 million. The €5.8 million tax benefit recognized from the derecognition of the deferred tax liability partially offset the €43.2 million expense, resulting in a net negative impact on equity that aligns with the reduction in total assets.

Leadership Changes

Chris Rabbat, Ph.D., has been appointed Chief Medical Officer, succeeding Fabio Cataldi, M.D., who will leave in Q4 2026. Tim Kelly has been appointed Chief Technical Officer to lead CMC, Quality, and IT functions. Both appointments are effective immediately.

Upcoming Catalysts

Abivax plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026. Topline results from the Phase 2b ENHANCE-CD induction trial are expected in mid-2027.

Abivax SA successfully concluded its pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod, targeting adults with moderately to severely active ulcerative colitis (UC). Announced on July 30, 2026, the clinical-stage biotechnology company secured constructive feedback that aligned regulatory expectations with its planned NDA submission strategy, confirming the content and format required for approval. This milestone validates the development path for obefazimod, a therapeutic designed to harness the body’s natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Abivax remains on track to submit its first NDA for the drug by the end of 2026, maintaining its timeline for potential market entry in the United States.

The interaction marked a critical step in the regulatory pathway for obefazimod, ensuring that the data package meets FDA standards for efficacy and safety. By achieving alignment on the submission strategy, Abivax reduces uncertainty regarding the review process and reinforces confidence in its late-stage development program. Marc de Garidel, Chief Executive Officer of Abivax, stated that achieving alignment with the FDA marks an important milestone as the company prepares to submit its first NDA. He noted that the Agency’s constructive feedback reinforces confidence in the path toward filing, building on the positive Phase 3 ABTECT program results announced earlier this year.

Regulatory Milestones and Timeline

Abivax emphasized that the positive outcome reflects strong engagement with regulators throughout the development process. The alignment on NDA content ensures that the company can proceed with compiling the final dossier without significant delays or unexpected requests for additional data. This efficiency is crucial for maintaining momentum in a competitive therapeutic landscape where speed to market can influence commercial success. The company’s focus on immune stabilization distinguishes obefazimod from other treatments in the ulcerative colitis space, offering a novel mechanism of action for patients who require effective long-term management of their condition.

What the Numbers Show

While no financial figures were disclosed in this announcement, the strategic value lies in de-risking the regulatory pathway for obefazimod. The completion of the pre-NDA meeting eliminates a major bottleneck that often delays biotech approvals. For investors, this signals that Abivax is executing its development plan as intended, with clear visibility into the next major milestone—the actual NDA submission by the end of 2026. The absence of requested additional studies or trials suggests that existing clinical data is sufficient to support approval, reinforcing the robustness of the drug’s profile.

Abivax continues to advance its pipeline with a focus on leveraging natural immune regulation to treat chronic inflammatory diseases. The successful pre-NDA interaction underscores the company’s ability to navigate complex regulatory environments while staying true to its scientific mission. As the end-of-2026 deadline approaches, stakeholders will closely monitor progress toward the formal submission, which could pave the way for obefazimod to become a new standard of care for ulcerative colitis patients.